Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis

  • Lisa Villabona
  • Emilia Andersson
  • Maddalena Marchesi
  • Giuseppe V. Masucci
Part of the Methods in Molecular Biology book series (MIMB, volume 1102)


The major histocompatibility complex (MHC) comprises a set of genes that are essential to immunity and surveillance against neoplastic transformation. MHC antigens not only regulate antitumor immune responses in experimental animal models but also directly correlate with survival and prognosis of patients with various types of cancers. Effective recognition of tumor cells by effector T cells may be affected by the genotype and the extent of expression of human leukocyte antigen (HLA)-peptide complexes. Therefore, MHC antigens may serve as potential biomarkers for prognosis and allow selection of cancer patients for specific therapy. We describe PCR-based method to determine the HLA genotype in healthy individuals and patients using blood and tumor tissue as DNA source.

Key words

HLA genotyping Ancestral haplotype 62.1 Malignant melanoma Survival HLA-A typing from formalin-fixed paraffin embedded tissue DNA 



Human leucocyte antigen


Major histocompatibility complex


Antigen presenting machinery


Ancestral HLA haplotype


Polymerase chain reaction


Malignant melanoma


Epithelial ovarian cancer


Overall survival


Time from diagnosis to first metastasis


Survival time from metastasis


Formalin fixed paraffin embedded


Peripheral blood lymphocytes



These studies were mainly supported by grants from the Cancer Society in Stockholm and the King Gustaf V Jubilee Fund and the Swedish Cancer Society, the Karolinska Institute/Stockholm County ALF grant. Sequences for HLA-A2 primers were kindly provided by Dr. Olle Olerup at Olerup SSP AB.


  1. 1.
    Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315(6017):301–305PubMedCrossRefGoogle Scholar
  2. 2.
    Hoon DS, Okamoto T, Wang HJ, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL (1998) Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16(4):1430–1437PubMedGoogle Scholar
  3. 3.
    Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI (2002) Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 9(6):587–593PubMedGoogle Scholar
  4. 4.
    Onishi T, Ohishi Y, Iizuka N, Imagawa K (1996) Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment. Int J Urol 3(6):435–440PubMedCrossRefGoogle Scholar
  5. 5.
    Franzke A, Buer J, Probst-Kepper M, Lindig C, Framzle M, Schrader AJ, Ganser A, Atzpodien J (2001) HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm 16(5):401–409PubMedCrossRefGoogle Scholar
  6. 6.
    Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC (1997) Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75(2):283–286PubMedCrossRefGoogle Scholar
  7. 7.
    So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K (2001) Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32(1):39–46PubMedCrossRefGoogle Scholar
  8. 8.
    Tisch M, Kyrberg H, Weidauer H, Mytilineos J, Conradt C, Opelz G, Maier H (2002) Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study. Laryngoscope 112(4):651–657PubMedCrossRefGoogle Scholar
  9. 9.
    Townsend ARM, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42(2):457PubMedCrossRefGoogle Scholar
  10. 10.
    Sioud M (2009) Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 70(6):516–525PubMedCrossRefGoogle Scholar
  11. 11.
    Campoli M, Ferrone S (2008) Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72(4):321–334PubMedCrossRefGoogle Scholar
  12. 12.
    Algarra I, Collado A, Garrido F (1997) Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res 16(4):373–380PubMedGoogle Scholar
  13. 13.
    Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 61:1243–1253Google Scholar
  14. 14.
    Browning M, Dunnion D (1997) HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 24(4):293–312PubMedCrossRefGoogle Scholar
  15. 15.
    Blomhoff A, Olsson M, Johansson S, Akselsen HE, Pociot F, Nerup J, Kockum I, Cambon-Thomsen A, Thorsby E, Undlien DE, Lie BA (2006) Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1*03 and DRB1*04 haplotypes. Genes Immun 7(2):130–140PubMedCrossRefGoogle Scholar
  16. 16.
    Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES (2001) Linkage disequilibrium in the human genome. Nature 411(6834):199–204PubMedCrossRefGoogle Scholar
  17. 17.
    Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225–2229PubMedCrossRefGoogle Scholar
  18. 18.
    Alper CA, Larsen CE, Dubey DP, Awdeh ZL, Fici DA, Yunis EJ (2006) The haplotype structure of the human major histocompatibility complex. Hum Immunol 67(1–2):73PubMedCrossRefGoogle Scholar
  19. 19.
    Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29(2):233–237PubMedCrossRefGoogle Scholar
  20. 20.
    Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abraham LJ, Dawkins RL (1992) Ancestral haplotypes: conserved population MHC haplotypes. Hum Immunol 34(4):242PubMedCrossRefGoogle Scholar
  21. 21.
    The MHC sequencing consortium (1999) Complete sequence and gene map of a human major histocompatibility complex. Nature 401(6756):921–923CrossRefGoogle Scholar
  22. 22.
    Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S (2004) Gene map of the extended human MHC. Nat Rev Genet 5(12):889–899PubMedCrossRefGoogle Scholar
  23. 23.
    Thorsby E (1997) Invited anniversary review: HLA associated diseases. Hum Immunol 53(1):1–11PubMedCrossRefGoogle Scholar
  24. 24.
    Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV (2006) Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103(1):145–150PubMedCrossRefGoogle Scholar
  25. 25.
    De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, Van Der Zanden HG, Masucci G (2004) Correlation between HLA-A2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality Rates. Med Oncol 21(1):49–52PubMedCrossRefGoogle Scholar
  26. 26.
    Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. (2012). Cancer Immunol Immunother 61(8):1243–1253PubMedCrossRefGoogle Scholar
  27. 27.
    Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, Salles G, Warzocha K (2007) Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin’s lymphoma. Genes Chromosomes Cancer 46(5):500–507PubMedCrossRefGoogle Scholar
  28. 28.
    Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R, Masucci GV (2009) The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 58(10):1599–1608PubMedCrossRefGoogle Scholar
  29. 29.
    Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005PubMedCrossRefGoogle Scholar
  30. 30.
    Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998PubMedCrossRefGoogle Scholar
  31. 31.
    Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14PubMedCrossRefGoogle Scholar
  32. 32.
    Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 56(5):709–717PubMedCrossRefGoogle Scholar
  33. 33.
    Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66(12):6405–6411PubMedCrossRefGoogle Scholar
  34. 34.
    Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT (1996) Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 2(4):641–652PubMedGoogle Scholar
  35. 35.
    Schipper RF, D’Amaro J, Bakker JT, Bakker J, van Rood JJ, Oudshoorn M (1997) HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 52(1):54–71PubMedCrossRefGoogle Scholar
  36. 36.
    Schipper RF, D’Amaro J, de Lange P, Schreuder GM, van Rood JJ, Oudshoorn M (1998) Validation of haplotype frequency estimation methods. Hum Immunol 59(8):518–523PubMedCrossRefGoogle Scholar
  37. 37.
    Svejgaard A, Ryder LP (1994) HLA and disease associations: detecting the strongest association. Tissue Antigens 43(1):18–27PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Lisa Villabona
    • 1
  • Emilia Andersson
    • 1
  • Maddalena Marchesi
    • 1
  • Giuseppe V. Masucci
    • 1
  1. 1.Department of Oncology-PathologyKarolinska Institute, Karolinska University HospitalStockholmSweden

Personalised recommendations